COVID-19 (Coronavirus)

Cardiac Amyloidosis

Cardiac amyloidosis is a condition often overlooked in medicine. But at the Smidt Heart Institute, our cardiologists and cardiac surgeons specialize in diagnosing and treating this rare condition, which often leads to heart failure.

"A patient with a suspected diagnosis of cardiac amyloidosis requires a comprehensive evaluation by a multidisciplinary team," said Jignesh Patel, MD, PhD. "At Cedars-Sinai, we have the capability to provide the patient with every service this condition might need."

These services begin with effective diagnosis using tools such as cardiac imaging, pathology and genetic testing. Patients in advanced stages of heart failure have access to the institute’s Mechanical Circulatory Support and Heart Transplantation programs.

In addition, Heart Institute experts are currently testing new drug therapies for cardiac amyloidosis. Although there is no cure for the disease, these therapies have the potential to stabilize or reverse it. For more information about cardiac amyloidosis studies, please see clinical trials.

For more information about referring a patient with suspected cardiac amyloidosis, please see contact us.